doi: 10.3389/fnut.2020.00143 Received 26 June 2020 Accepted 21 July 2020 Published 02 September 2020 Volume 7 - 2020 Edited by Christophe Matthys, KU Leuven, Belgium Reviewed by Alan Diamond, University of Illinois at Chicago, United States
Studies suggest that intravenous glutathione reduces and protects against toxicity, cancer side effects, improves or maintains quality of life, and enhances therapeutic effects in some cancer patients treated with certain chemotherapy agents
A healthcare provider may prescribe a compounded drug if determined that it is medically appropriate and necessary for you
The ability of silymarin to prevent cell damage is also thought to sustain Glutathione levels
Posted December 7, 2025 Reviewed by Kaja Perina Key points 22% of GLP-1 patients develop nutritional deficiencies within 12 months, vitamin D being the most common
The review also involved two studies examining how the drug liraglutide may treat RA